ERR2598228
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_forebrain
- 8
- umap1_2d
- -4.449506534
- umap2_2d
- 2.164674382
- umap1_3d
- -2.018540651
- umap2_3d
- 2.549562212
- umap3_3d
- -2.19026661
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.650
- MYC_TARGETS_V2+0.600
- G2M_CHECKPOINT+0.570
- MYC_TARGETS_V1+0.550
- DNA_REPAIR+0.430
- WNT_BETA_CATENIN_SIGNALING+0.250
- UNFOLDED_PROTEIN_RESPONSE+0.240
- MITOTIC_SPINDLE+0.180
- SPERMATOGENESIS+0.180
- HEDGEHOG_SIGNALING+0.160
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.440
- INFLAMMATORY_RESPONSE-0.380
- UV_RESPONSE_DN-0.380
- INTERFERON_GAMMA_RESPONSE-0.370
- ALLOGRAFT_REJECTION-0.360
- PROTEIN_SECRETION-0.360
- IL2_STAT5_SIGNALING-0.290
- IL6_JAK_STAT3_SIGNALING-0.290
- COMPLEMENT-0.280
- KRAS_SIGNALING_UP-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598252 | fetal | fetal | 0.919 |
| 2 | ERR2598256 | fetal | fetal | 0.906 |
| 3 | BS_8SKZ7BRN | low-grade glioma | — | 0.905 |
| 4 | ERR2598250 | fetal | fetal | 0.904 |
| 5 | MNG715 | — | — | 0.894 |
| 6 | MNG497 | — | — | 0.889 |
| 7 | ERR2598235 | fetal | fetal | 0.884 |
| 8 | SJEPD036_D.RNA-Seq | EPN | Supratentorial EPN | 0.884 |
| 9 | MDT-AP-3401 | Med | Medulloblastoma | 0.881 |
| 10 | TCGA-77-8148-01A-11R-2247-07 | — | cohortSQ2 | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.650 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.550 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.430 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.040 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.010 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.010 | Inavolisib | — uncovered |